V-Test(688372)
Search documents
聚利宝控股走妖 股价一度暴涨53.03%
Zheng Quan Shi Bao Wang· 2024-10-21 02:12
Group 1 - The stock of Julebao Holdings experienced a significant surge, with an increase of 0.07 HKD, representing a rise of 53.03% compared to the previous trading day [1] - The opening price of Julebao Holdings was 0.15 HKD, reaching a peak price of 0.20 HKD, with a current increase of approximately 17% [1]
欧普泰涨停 48只北交所个股涨超10%
Zheng Quan Shi Bao Wang· 2024-10-21 02:11
10月21日盘中北交所股欧普泰涨停,截至09:47,股价报11.25元,成交0.54亿元,换手率9.46%,振幅 25.64%。 北交所个股中,截至发稿上涨的共有250只,涨幅在10%以上的共有48只,涨停的有恒拓开源、天马新 材、华岭股份等,下跌的有4只,跌幅较大的有锦好医疗、中设咨询、方大新材,分别下跌1.21%、 0.88%、0.80%。 (数据宝)北交所股票盘中涨幅排名代码简称收盘价(元)涨跌幅(%)换手率(%)834415 恒拓开源 18.12 29.99 6.34838971 天马新材 50.16 29.98 0.40430139 华岭股份 26.23 29.98 5.28835179 凯德石英 39.55 29.97 12.24430489 佳先股份 22.77 29.97 1.68832662 方盛股份 18.14 29.94 34.19836807 奔朗新材 8.64 29.92 7.05836414 欧普泰 11.25 29.91 9.46832149 利尔达 9.17 29.89 16.99873570 坤博精工 46.00 28.35 30.30833346 威贸电子 24.88 24 ...
威贸电子涨停 46只北交所个股涨超10%
Zheng Quan Shi Bao Wang· 2024-10-21 02:11
10月21日盘中北交所股威贸电子涨停,截至09:49,股价报25.97元,成交1.92亿元,换手率29.97%,振 幅21.02%。 北交所个股中,截至发稿上涨的共有248只,涨幅在10%以上的共有46只,涨停的有恒拓开源、天马新 材、华岭股份等,下跌的有6只,跌幅较大的有锦好医疗、方大新材、中设咨询,分别下跌1.51%、 1.46%、0.88%。 (数据宝)北交所股票盘中涨幅排名代码简称收盘价(元)涨跌幅(%)换手率(%)834415 恒拓开源 18.12 29.99 6.36838971 天马新材 50.16 29.98 0.41430139 华岭股份 26.23 29.98 5.30833346 威贸电子 25.97 29.98 29.97835179 凯德石英 39.55 29.97 12.34430489 佳先股份 22.77 29.97 1.69832662 方盛股份 18.14 29.94 34.19836807 奔朗新材 8.64 29.92 8.66836414 欧普泰 11.25 29.91 10.45832149 利尔达 9.17 29.89 17.31873570 坤博精工 45.60 ...
电投产融复牌涨停 拟置换资产转型核电资产整合平台
Zhong Guo Jing Ji Wang· 2024-10-21 02:11
中国经济网北京10月21日讯 电投产融(000958.SZ)开盘一字涨停,截止发稿时报4.50元,涨幅10.02%。 电投产融10月18日晚披露《关于披露重组预案暨公司股票复牌的公告》,公司正在筹划重大资产重组事 项,拟通过发行股份方式购买国电投核能有限公司控股权,同时置出国家电投集团资本控股有限公司控 股权,并将视具体情况募集配套资金。 本次交易预计构成重大资产重组及关联交易,同时不构成实际控制人变更。 公司股票已于2024年9月30日(星期一)开市时起停牌,经向深圳证券交易所申请,公司股票将于2024 年10月21日(星期一)开市起复牌。 电投产融同日披露《重大资产置换及发行股份购买资产并募集配套资金暨关联交易预案》称,本次交易 由重大资产置换、发行股份购买资产及募集配套资金组成。 本次交易的拟置入资产为国家核电技术有限公司(简称"国家核电")及中国人寿合计持有的国电投核能 有限公司(简称"电投核能")100%股权,拟置出资产为上市公司所持的国家电投集团资本控股有限公 司(简称"资本控股")100%股权。 上市公司拟以所持的资本控股100%股权与国家核电所持有的电投核能股权的等值部分进行置换;针对 置入资 ...
恒帅股份解禁市值逾40亿元,实控人与一致行动人意见现分歧
Zheng Quan Shi Bao Wang· 2024-10-21 02:01
Group 1 - The total scale of restricted shares in A-shares has decreased to over 30 billion yuan this week, with 56 companies having their restricted shares unlocked, totaling 2.28 billion shares and a market value of 32.66 billion yuan [1] - Among the companies, Hengshuai Co., Ltd. (300969.SZ) has the largest unlock scale exceeding 4 billion yuan, followed by Huaci Co., Ltd. (001216.SZ), High-speed Rail Electric (688285.SH), and Siquan New Materials (301489.SZ), each with unlock values exceeding 2 billion yuan [1] - Hengshuai Co., Ltd. has committed to not reducing its shareholdings from October 22, 2024, to April 21, 2025, despite the controlling shareholder's inconsistent intentions regarding share reduction [1][2] Group 2 - The company has seen a significant stock price fluctuation, with a year-to-date decline of approximately 20%, despite an increase of 247% from its IPO price of 20.68 yuan per share to the latest closing price of 71.78 yuan per share [1] - Hengshuai Co., Ltd. reported a revenue of 463 million yuan in the first half of the year, representing a year-on-year growth of 16.25%, and a net profit of 116 million yuan, up 26.52% year-on-year [1] - The company is expanding its electric motor products into industrial automation and humanoid robot markets, indicating potential growth opportunities [2] Group 3 - Huaci Co., Ltd. has 189 million shares unlocked on October 21, representing 75% of its total share capital, with a market value of approximately 2.369 billion yuan, leading to a 300% increase in its circulating shares [3] - The company reported a revenue of 581 million yuan in the first half of the year, with a year-on-year growth of 4.33%, and a net profit of 99 million yuan, up 17.25% year-on-year [3] - The market impact of the unlock of restricted shares is significant, with six companies having over 50% of their total share capital unlocked this week [3]
第二主业连续多年亏损 正海磁材拟"壮士断腕"
Zhong Guo Jing Ji Wang· 2024-10-21 02:00
Core Viewpoint - Zhenghai Magnetic Materials (300224.SZ) is planning to optimize and shrink its electric motor drive system business due to continuous losses, which have significantly impacted the company's overall performance [1][2]. Group 1: Business Overview - Zhenghai Magnetic Materials entered the electric motor drive system sector through the acquisition of Shanghai Dajun Power Control Technology Co., Ltd. in 2014, viewing it as a second growth curve [1][2]. - Shanghai Dajun, established in 2005, focuses on the research, production, and sales of electric motor drive systems and related technologies [1]. - The company initially aimed to diversify its revenue streams by combining high-performance neodymium-iron-boron permanent magnet materials with electric motor drive systems [1][2]. Group 2: Financial Performance - Since 2020, the electric motor drive system business has been consistently losing money, with revenue contribution remaining below 2%, leading to significant operational challenges for the company [1][3]. - Shanghai Dajun's net profits from 2018 to 2024 have shown continuous losses, with figures such as -40.29 million, -105.26 million, and -33.58 million [3]. - In contrast, the high-performance neodymium-iron-boron permanent magnet materials business has seen revenue growth, reaching a peak of 6.228 billion in 2022, although it declined to 5.77 billion in 2023 due to falling raw material prices [3]. Group 3: Strategic Response - The company is authorizing its management to determine strategies for optimizing and shrinking the electric motor drive system business in light of its current operational status and future industry development plans [2]. - The decision to restructure comes after the realization that the electric motor drive system business is facing severe competition and market challenges, including vertical integration by automakers and aggressive pricing strategies [1][2].
募资额缩减逾四成 兄弟科技欲扩大造影剂产能
Zhong Guo Jing Ji Wang· 2024-10-21 02:00
Core Viewpoint - Brothers Technology (002562.SZ) has announced a new financing plan to raise 442 million yuan for the construction of a 600-ton iodinated contrast agent raw material project, aiming to enhance its market share and industry position in the iodinated contrast agent market. The latest fundraising amount has been reduced by over 40% compared to the initial plan, and the supplementary working capital project has been canceled [1][2]. Financing Plan - The company plans to issue shares to no more than 35 specific investors, with the issuance price set at no less than 80% of the average trading price over the previous 20 trading days [1]. - The total amount raised in direct financing since the company's listing has reached 2.603 billion yuan, with cumulative cash dividends of only 390 million yuan, indicating a significant disparity between financing and dividends [1][2]. Market Dynamics - The iodinated contrast agent market is expected to undergo significant changes due to the expansion of competitors and the entry of new players, with the market structure shifting as companies increase production capacity [1][4]. - The global contrast agent market has grown from $4.999 billion in 2016 to $6.672 billion in 2021, with a compound annual growth rate (CAGR) of 5.94%. In contrast, China's iodinated contrast agent market has seen an average growth rate of around 12% during the same period [2][3]. Production Capacity and Sales - Brothers Technology's iodinated contrast agent raw materials, including iopamidol, have shown increasing sales revenue from 49.32 million yuan in 2020 to 165.65 million yuan in 2022 [3]. - The company has established a solid customer base for its iodinated contrast agent raw materials, with significant orders already in hand, ensuring capacity utilization for the new project [3][5]. Competitive Landscape - The iodinated contrast agent market is characterized by high concentration, with major players like GE and domestic leader Sihuan Pharmaceutical holding significant market shares. Brothers Technology aims to increase its production capacity to 700 tons of iopamidol, positioning itself as a key player in the domestic market [4]. - Despite the growth potential, Brothers Technology has faced challenges with negative gross margins in its iodinated contrast agent raw materials segment, indicating the need for improved pricing and cost management strategies [4][5].
海大集团:海外产能整体较为紧张 正积极扩大产能
Zheng Quan Shi Bao Wang· 2024-10-21 01:58
证券时报e公司讯,海大集团(002311)在业绩说明会表示,海外产能整体较为紧张,因此,公司正在积 极以多种方式扩大相关区域产能布局。 另外,今年生猪养殖成本逐步下降。 主要是大宗农产品原材料价格下行,带动整体饲料成本持续下降。 ...
欧菲光连收3个涨停板
Zheng Quan Shi Bao Wang· 2024-10-21 01:57
证券时报网讯,欧菲光盘中涨停,已连收3个涨停板,截至9:33,该股报12.91元,换手率7.48%,成交 量2.43亿股,成交金额31.05亿元,涨停板封单金额为2941.16万元。 连续涨停期间,该股累计上涨33.09%,累计换手率为44.68%。 最新A股总市值达427.30亿元,A股流通市值419.70亿元。 ...
海能达录得18天14板
Zheng Quan Shi Bao Wang· 2024-10-21 01:57
证券时报网讯,海能达再度涨停,18个交易日内录得14个涨停,累计涨幅为267.32%,累计换手率为 397.31%。 截至9:49,该股今日成交量1.88亿股,成交金额23.87亿元,换手率14.69%。 最新A股总市值达239.10亿元,A股流通市值168.62亿元。 ...